MedPath

Neuroregeneration Enhanced by Transcranial Direct Current Stimulation (TDCS) in Stroke

Not Applicable
Completed
Conditions
Stroke
Interventions
Device: DC-Stimulator to apply tDCS
Device: DC-Stimulator to apply Sham tDCS
Registration Number
NCT00909714
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Brief Summary

Testing the hypothesis that non-invasive brain stimulation by transcranial direct current stimulation (tDCS) combined with functional training in the subacute phase of first-ever stroke will enhance functional regeneration compared with a Placebo intervention.

Detailed Description

Stroke is the leading cause of long-term disability, which significantly impairs the economic and social life of patients and society. Every year 200 000 to 250 000 patients suffer a stroke in Germany. Only a small number of the stroke survivors recover to a degree that allows them to return into their professional and private life. Despite significant efforts to develop novel and efficient treatment strategies the level of functional regeneration is still not satisfying. Thus, the development of innovative and effective treatment strategies will have a major impact for the patients' life, the society and the public health system.

Within the proposed project an innovative, non-invasive and cost effective interventional strategy, based on the combination of a specific rehabilitative training and brain stimulation by transcranial direct current stimulation (tDCS), will be used to enhance functional regeneration in stroke patients. The intervention will be applied in an early stage in which plasticity, cortical reorganization and functional improvement is most pronounced. We hypothesize that the combination of anodal tDCS delivered to the motor cortex of the affected hemisphere combined with training over a period of two weeks in the subacute stage after stroke will significantly enhance cortical plasticity, functional regeneration and long-term outcome determined by clinical and functional outcome measures compared with Placebo stimulation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
119
Inclusion Criteria
  • Subacute stroke patients (5-45 days after stroke) with thromboembolic non-hemorrhagic subcortical or cortical, first clinically overt stroke will be included. Moderate to moderately severe upper-extremity hemiparesis, defined as an Upper Extremity Fugl-Meyer score (UEFMA) between 20 and 58 (inclusive).
Exclusion Criteria
  • pre-existing large lesions (> 1.5 cm maximum diameter) in a brain area that belongs to the anatomically established sensorimotor/premotor system
  • progressive stroke
  • completely lesioned hand knob area of M1 affected if no motor evoked potentials (MEPs) elicited by transcranial magnetic stimulation (TMS) are present
  • bilateral motor impairment
  • florid alcohol and/or drug abuse
  • florid severe psychiatric illness (e.g. schizophrenia)
  • severe language disturbances that prevents the patient to give informed consent or inhibit adequate scoring because of insufficient understanding of scoring introductions
  • tumor diseases with a life expectancy less than one year
  • increased intracranial pressure
  • polyneuropathy and/or ischemic peripheral disease if the sensorimotor functions of the upper extremities are affected clinically relevant
  • severe cognitive deficits (MMSE ≤ 23)
  • pregnancy
  • contraindication for MRI or TMS

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Anodal tDCSDC-Stimulator to apply tDCSDirect Current (DC)-Stimulator to apply tDCS + Training
Sham tDCSDC-Stimulator to apply Sham tDCSDirect Current (DC)-Stimulator to apply Sham tDCS (Placebo) + Training
Primary Outcome Measures
NameTimeMethod
Upper Extremity Fugl-Meyer-Assessment (UEFMA)1-7 days after the end of the intervention

standardized test of upper extremity function

Secondary Outcome Measures
NameTimeMethod
Upper Extremity Fugl-Meyer-Assessment (UEFMA) | Long-term outcome12±1 months after the intervention

standardized test of upper extremity function

Action Research Arm Test (ARAT)90±20 days after the intervention

standardized tests of upper extremity function

Grip Force12±1 months after the intervention

dynamometer-based test to assess grip strength

Upper Extremity Fugl-Meyer-Assessment (UEFMA)90±20 days after the intervention

standardized test of upper extremity function

Stroke Impact Scale (SIS)90±20 days after the intervention

questionnaire is to evaluate how stroke has impacted health and life of patients

Action Research Arm Test (ARAT) | Long-term outcome12±1 months after the intervention

standardized tests of upper extremity function

Nine Hole Peg Test (NHPT)90±20 days after the intervention

standardized test to assess fine motor skills

Nine Hole Peg Test (NHPT) | Long-term outcome12±1 months after the intervention

standardized test to assess fine motor skills

Stroke Impact Scale (SIS) | Long-term outcome12±1 months after the intervention

questionnaire is to evaluate how stroke has impacted health and life of patients

Box-and-Block Test12±1 months after the intervention

standardized test to assess fine motor skills

Trial Locations

Locations (11)

University Medical Center Heidelberg

🇩🇪

Heidelberg, Germany

MEDIAN Klinik Berlin-Kladow

🇩🇪

Berlin, Germany

Neurologische Klinik Bad Aibling

🇩🇪

Bad Aibling, Germany

University Medical Center Hamburg Eppendorf (UKE)

🇩🇪

Hamburg, Germany

Neurologische Universitätsklinik Wien

🇦🇹

Wien, Austria

Klinik Kipfenberg

🇩🇪

Kipfenberg, Bayern, Germany

Brandenburgklinik Berlin-Brandenburg

🇩🇪

Bernau bei Berlin, Berlin, Germany

Neurologisches Zentrum Segeberger Kliniken

🇩🇪

Bad Segeberg, Germany

NRZ Leipzig

🇩🇪

Bennewitz, Germany

Neurologie Moritzklinik

🇩🇪

Bad Klosterlausnitz, Thüringen, Germany

Fondazione Santa Lucia

🇮🇹

Rome, Italy

© Copyright 2025. All Rights Reserved by MedPath